NCT06742671 Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
| NCT ID | NCT06742671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Groupe Hospitalier de la Rochelle Ré Aunis |
| Condition | Giant Cell Arteritis (GCA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-02-14 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-02-14 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Giant cell arteritis is a vasculitis, i.e. inflammation of the artery walls, which generally affects people over the age of 50. Diagnosis can be long and difficult, as the clinical signs are not specific (headache, pain in the jaw, scalp, shoulders and/or pelvis, abdominal pain, weight loss, etc.), but it must be made quickly, given the risk of complications. The reference method for diagnosis was initially based on clinical suspicion and analysis of a "piece of temporal artery" (biopsy) performed in the operating theatre under local anaesthetic. Since the mid-1990s, improvements in ultrasound techniques have made it possible to identify a sign, known as a halo, on the temporal arteries that is typical of patients with Giant Cell Arteritis. A prospective multicenter study published in 2024 demonstrated that, in patients with a clinical suspicion of Giant Cell Arteritis, if a halo was found on both temporal arteries by ultrasound, there was no need for a biopsy. This study is at the origin of a change in practices in the diagnosis and care of patients suffering from this disabling disease. To facilitate early diagnosis, a fast-track pathway has been set up. The aim is to make a rapid diagnosis, thereby reducing the risk of after-effects, shortening the length of hospital stays, considering outpatient treatment and limiting the number of biopsies. The investigators propose to evaluate the performance of this fast-track pathway.
Eligibility Criteria
Inclusion Criteria: * Patient suspected of GCA Exclusion Criteria: * Opposition to the use of their data
Contact & Investigator
Christophe RONCATO, MD
STUDY DIRECTOR
Groupe Hospitalier de la Rochelle Ré Aunis
Frequently Asked Questions
Who can join the NCT06742671 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Giant Cell Arteritis (GCA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06742671 currently recruiting?
Yes, NCT06742671 is actively recruiting participants. Contact the research team at caroline.allix-beguec@ght-atlantique17.fr for enrollment information.
Where is the NCT06742671 trial being conducted?
This trial is being conducted at La Rochelle, France.
Who is sponsoring the NCT06742671 clinical trial?
NCT06742671 is sponsored by Groupe Hospitalier de la Rochelle Ré Aunis. The principal investigator is Christophe RONCATO, MD at Groupe Hospitalier de la Rochelle Ré Aunis. The trial plans to enroll 100 participants.